TABLE 5.
Results for the cost utility analysis.
| Total cost (US$) | LY | QALY | Δ cost (US$) | ΔQALY | ICER (US$/QALY) | |
|---|---|---|---|---|---|---|
| Overall population | ||||||
| Sintilimab plus chemotherapy | 15,399.21 | 1.44 | 0.90 | 7,923.63 | 0.30 | 26,773.68 |
| Chemotherapy alone | 7,475.58 | 1.04 | 0.61 | NA | NA | NA |
| Population with PD-L1 CPS ≥ 10 | ||||||
| Sintilimab plus chemotherapy | 15,656.19 | 1.39 | 0.89 | 6,493.43 | 0.22 | 30,065.50 |
| Chemotherapy alone | 9,162.77 | 1.08 | 0.68 | NA | NA | NA |
Abbreviation: QALYs, quality-adjusted life-years; ICER, incremental cost-effectiveness ratio; NA, Not applicable; Note: Δ, incremental